Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
Fig 2
The effects of olaparib, triapine, and cediranib combinations on the growth of subcutaneous OVCAR3 xenografts in mice.
Athymic nude mice were inoculated s.c with OVCAR3 cells. After 10 days, mice were randomly assigned to 6 groups (n = 5) and treated i.p. with vehicle, cediranib (0.75 mg/kg), olaparib (50 mg/kg) plus cediranib, triapine (10 mg/kg) plus cediranib, olaparib plus triapine, and olaparib plus triapine plus cediranib daily for consecutive 6 weeks (day 10 to 52). (A) Tumor size was measured every 2–3 days. Data are means ± SE. p values were determined by the Wilcoxon matched-pairs signed test compared with control and between groups. (B) Tumor tissue was excised from mice, photographed, and weighted in the end of the experiment. Data are means ± SE. p values were determined by the one-way ANOVA with the Dunnett’s multiple comparison test compared with the control. (C) Representative images of H&E-stained section of tumor tissue from each treatment group are shown. (D) The body weight of mice was measured every 2–3 days. The means of body weight for all treatment groups are shown.